$3.73
0.0852.33%
Last update: Nov 10, 2:49 PM
Immuneering Corp
IMRXNASDAQ
Immuneering fell 47.2% from $6.91 to $3.65, behind the S&P 500's +10.5%. Its worst day was Jan 8 (−43.2%), and its low came Nov 5 at $3.37.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.38 beat the $-0.38 estimate on $0.00 revenue.
−2.6% · S&P 500 −1.7%
Immuneering closed at its highest level of the year, 20.5% above where the year started.
Story events cover the past 12 months · Times ET
+24.0%, the year's best day · S&P 500 −0.3%
EPS of $-0.18 beat the $-0.31 estimate on $0.00 revenue.
+7.0% · S&P 500 −1.3%
EPS of $-0.21 beat the $-0.26 estimate on $0.00 revenue.
+0.4% · S&P 500 −1.2%
- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs.
−22.1% · S&P 500 +0.3%
EPS of $-0.27 beat the $-0.27 estimate on $0.00 revenue.
−0.2% · S&P 500 −0.2%
EPS of $-0.37 missed the $-0.30 estimate on $0.00 revenue.
−6.8% · S&P 500 −1.8%
Where it ended: a close of $3.65 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 5, 2027 (EPS est. $-0.40).
Nothing in the past 12 months.
All IMRX dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IMRX and SPY from Benzinga historical bars. Not investment advice.
